Oppenheimer lowered the firm’s price target on Achieve Life Sciences to $11 from $18 and keeps an Outperform rating on the shares. The firm notes Achieve Life Sciences’ EPS slightly missed both its estimate and Street consensus. As Oppenheimer’s focus remains on the smoking cessation program, the firm is pleased to see that the single open-label study remains on track to initiate in May.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV:
- Achieve Life Sciences reports Q1 EPS (26c), consensus (24c)
- Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
- ACHV Earnings this Week: How Will it Perform?
- Achieve Life Sciences announces publication of vaping cessation trial results
- Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine